Value, not price: Gilead defends Sovaldi premium pricing
By Jennifer Boggs
Tuesday, January 14, 2014
SAN FRANCISCO – Gilead Sciences Inc.’s breakthrough hepatitis C virus (HCV) drug Sovaldi (sofosbuvir), which gained approval in the U.S. in December and got off to a strong start despite typical slowdown of the holidays, is expected to be approved in Europe later this month, likely with favorable pricing.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.